The aim of the research was to investigate prognostic factors in patients with resected colorectal liver metastases (CLMs) after biological and chemotherapy, which made initially unresectable disease suitable for resection. Sixty-six patients with resected CLMs, operated after induction bio-chemotherapy with bevacizumab + FOLFOX4, treated at the Clinic of Oncology, Clinical Center Niš from 2010 - 2017 were included. Disease-free survival (DFS) and overall survival (OS) were estimated using the Kaplan-Meier method and compared using the log-rank test according to demographic characteristics, characteristics of the disease and the treatment. A univariate COX regression analysis was performed. In patients with up to 4 CLMs, DFS was significantly longer than in patients with five or more metastases (18,384 v.s. 6,85 months; p < 0,001). Significantly longer OS was present in patients with up to four CLMs than in those with five or more CLMs (44,687 v.s. 29,723 months; p=0,006) and in patients without extrahepatic disease (41,71 v.s. 23,283 months; p=0,012). In the univariate analysis, five or more CLMs were predictors of poorer DFS (HR 3,989; 95% CI 1,055 - 15,087; p = 0,042), whereas the absence of extrahepatic disease was a predictor of better OS (HR 0,122; 95% CI 0,017 - 0,869; p = 0,036). Results of this research are in concordance with previous larger studies in patients with resected CLMs. The number of hepatic and the presence of extrahepatic metastases are prognostic parameters in patients with resected CLM after conversion bio-chemotherapy.
References
1.
Minagawa M, Makuuchi M, Torzilli G, Takayama T, Kawasaki S, Kosuge T, et al. Extension of the Frontiers of Surgical Indications in the Treatment of Liver Metastases From Colorectal Cancer. Annals of Surgery. 2000;231(4):487–99.
2.
Dzunic M, Petkovic I, Cvetanovic A. Current and future targets and therapies in metastatic colorectal cancer. J BUON. 2019;24(5):1785–92.
3.
Wang Z, Wang X, Zhang Z, Wang X, Chen M, Lu L, et al. Association between Primary Tumor Location and Prognostic Survival in Synchronous Colorectal Liver Metastases after Surgical Treatment: A Retrospective Analysis of SEER Data. Journal of Cancer. 2019;10(7):1593–600.
4.
Doci R, Gennari L, Bignami P, Montalto F, Morabito A, Bozzetti F. One hundred patients with hepatic metastases from colorectal cancer treated by resection: Analysis of prognostic determinants. Journal of British Surgery. 1991;78(7):797–801.
5.
Taylor M, Forster J, Langer B, Taylor BR, Greig PD, Mahut C. A study of prognostic factors for hepatic resection for colorectal metastases. The American Journal of Surgery. 1997;173(6):467–71.
6.
Baldessari C, Spallanzani A, Gelsomino F, Bettelli S, Pugliese G, Salati M, et al. Outcome and prognostic factors after resection of liver metastases in patients with colorectal cancer. Annals of Oncology. 2017;28:vi13–4.
7.
de Haas RJ, Wicherts DA, Salloum C, Andreani P, Sotirov D, Adam R, et al. Long‐term outcomes after hepatic resection for colorectal metastases in young patients. Cancer. 2010;116(3):647–58.
8.
Dzunic M, Andjelkovic-Apostolovic M, S V. Survival of patients with liver metastases from colorectal cancer treated with bevacizumab and FOLOFOX4. J BUON. 2020;25(1):212–9.
9.
Lieu CH, Renfro LA, de Gramont A, Meyers JP, Maughan TS, Seymour MT, et al. Association of Age With Survival in Patients With Metastatic Colorectal Cancer: Analysis From the ARCAD Clinical Trials Program. Journal of Clinical Oncology. 2014;32(27):2975–82.
10.
Donadon M, Lleo A, Di Tommaso L, Soldani C, Franceschini B, Roncalli M, et al. The Shifting Paradigm of Prognostic Factors of Colorectal Liver Metastases: From Tumor-Centered to Host Immune-Centered Factors. Frontiers in Oncology. 8.
11.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2018;68(6):394–424.
12.
Scheele J, Stangl R, Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: Impact of surgical resection on the natural history. Journal of British Surgery. 1990;77(11):1241–6.
13.
Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical Score for Predicting Recurrence After Hepatic Resection for Metastatic Colorectal Cancer. Annals of Surgery. 1999;230(3):309.
14.
Imai K, Adam R, Baba H. How to increase the resectability of initially unresectable colorectal liver metastases: A surgical perspective. Annals of Gastroenterological Surgery. 2019;3(5):476–86.
15.
Horowitz M, Neeman E, Sharon E, Ben-Eliyahu S. Exploiting the critical perioperative period to improve long-term cancer outcomes. Nature Reviews Clinical Oncology. 2015;12(4):213–26.
16.
Neeman E, Ben-Eliyahu S. Surgery and stress promote cancer metastasis: New outlooks on perioperative mediating mechanisms and immune involvement. Brain, Behavior, and Immunity. 2013;30:S32–40.
17.
Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, et al. Rescue Surgery for Unresectable Colorectal Liver Metastases Downstaged by Chemotherapy. Annals of Surgery. 2004;240(4):644–58.
18.
Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Annals of Oncology. 2016;27(8):1386–422.
19.
Engstrand J, Nilsson H, Strömberg C, Jonas E, Freedman J. Colorectal cancer liver metastases – a population-based study on incidence, management and survival. BMC Cancer. 2018;18(1).
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
